REFERENCES
  1. Meissner HC. Viral Bronchiolitis in Children. N Eng J Med 2016;374:62-72.
  2. Ralston SL, Lieberthal AS, Meissner HC, Alverson BK, Baley JE, Gadomski AM, Johnson DW, Light MJ, Maraqa NF, Mendonca EA, et al. Clinical Practice Guideline: The Diagnosis, Management and Prevention of Bronchiolitis. Pediatrics 2014;134(5):e1474–502.
  3. Brice DC, Diamond G. Antiviral activities of human host defense peptides. Curr Med Chem 2020;27(9):1420–43.
  4. Ahmed A, Siman-Tov G, Hall, G, Bhala N, Narayanan A. Human Antimicrobial Peptides as Therapeutics for Viral Infections. Viruses 2019; 11(8):704.
  5. Elnagdy S, Alkhazindar M. The Potential of Antimicrobial Peptides as an Antiviral against COVID-19. ΑCS Pharmacol Transl Sci 2020;3(4):780–782.
  6. Harcourt JL, McDonald M, Svoboda P, Pohl J, Tatti K, Haynes LM. Human cathelicidin, LL-37, inhibits respiratory syncytial virus infection in polarized airway epithelial cells. BMC Res Notes 2016;9:11.
  7. Tripathi S, Wang G, White M, Qi L, Taubenberger J, Hartshorn KL. Antiviral Activity of the Human Cathelicidin, LL-37, and Derived Peptides on Seasonal and Pandemic Influenza A Viruses. PLoS ONE 2015;10(4):e0124706.
  8. Sousa FH, Casanova V, Findlay F, Stevens C, Svoboda P, Pohl J, Proodfoot L, Barlow PG. Cathelicidins display conserved direct antiviral activity towards rhinovirus. Peptides 2017;95:76–83.
  9. Currie SM, Findlay EG, McFarlane AJ, Fitch PM, Bottcher B, Colegrave N, Paras A, Jozwik A, Chiu C, Schwarze J, et al. Cathelicidins have direct antiviral activity against respiratory syncytial virus in vitro and protective function in vivo in mice and humans. J Immunol 2016;196(6):2699-710.
  10. Barlow PG, Svoboda P, Mackellar A, Nash AA, York IA, Pohl J, Davidson DJ, Donis RO. Antiviral activity and increased host defense against influenza infection elicited by the human cathelicidin LL-37. PLoS ONE 2011;6(10):e25333.
  11. Szymczak I, Pawliczak R. The Active Metabolite of Vitamin D3 as a Potential Immunomodulator. Scand J Immunol 2016;83(2):83-91.
  12. Svensson D, Nebel D, Nilsson B. Vitamin D3 modulates the innate immune response through regulation of the hCAP-18/LL-37 gene expression and cytokine production. Inflamm Res 2016;65(1):25-32.
  13. Wang EE, Milner R, Allen U, Maj H. Bronchodilators for treatment of mild bronchiolitis: a factorial randomised trial. Arch Dis Child 1992;67:289–93.
  14. Wang EE, Milner RA, Navas L, Maj H. Observer agreement for respiratory signs and oximetry in infants hospitalized with lower respiratory infections. Am Rev Respir Dis 1992;145(1):106–9.
  15. Seng QB, Chin HJ. Reliability and Validity of Respiratory Score in the Assement of Acute Bronchiolitis. Malays J Med Sci 2004;11(2):34-40.
  16. Mansbach JM, Piedra PA, Borregaard N, Martineau AR, Neuman MI, Espinola JA, Camargo CA. Serum cathelicidin level is associated with viral etiology and severity of bronchiolitis. J Allergy Clin Immunol 2012;130:1007-8.
  17. Mansbach JM, Hasegawa K, Ajami NJ, Petrosino JF, Piedra PA, Tierney CN, Espinola JA, Camargo CA. Serum LL-37 level is associated with severity of bronchiolitis and viral etiology. Clin Infect Dis 2017;65:967-75.
  18. Hasegawa K, Mansbach JM, Ajami NJ, Petrosino JF, Freishtat RJ, Teach SJ, Piedra PA, Camargo CA. Serum cathelicidin, nasopharyngeal microbiota, and disease severity among infants hospitalized with bronchiolitis. J Allergy Clin Immunol 2017; 139:1383–6.
  19. Stukes TM, Shary JR, Wei W, Ebeling MD, Dezsi KB, Shary FS, Forestieri NE, Hollis BW, Wagner CL. Circulating Cathelicidin Concentrations in a Cohort of Healthy Children: Influence of Age, Body Composition, Gender and Vitamin D Status. PLoS ONE 2016;11(5): e0152711.
  20. Davidopoulou S, Diza E, Menexes G, Kalfas S. Salivary concentration of the antimicrobial peptide LL-37 in children. Arch Oral Biol 2012;57(7):865–9.
  21. Alvarez-Rodriguez L, Lopez-Hoyos M, Garcia-Unzueta M, Amado JA, Cacho PM, Martinez-Taboada VM. Age and low levels of circulating vitamin D are associated with impaired innate immune function. J Leukoc Biol 2012; 91(5):829-38.
  22. Ertugrul AS, Sahin H, Dikilitas A, Alpalsan NZ, Bozoglan A, Tekin Y. Gingival crevicular fluid levels of human beta-defensin-2 and cathelicidin in smoker and non-smoker patients: a cross-sectional study. J Periodont Res 2014;49(3):282-9.
  23. Soldati KR, Toledo FE, Aquino SG, Rossa Jr C, Deng D, Zandim-Barcelos DL. Smoking reduces cathelicidin LL37 and human neutrophil peptide 1-3 levels in the gingival crevicular fluid of patients with periodontitis. J Periodont. 2020: doi.org/10.1002/JPER.20-0098.
  24. Havelka AM, Yektaei-Karin E, Hultenby K, Sorensen OE, Lundahl J, Berggren V, Marchini G. Maternal plasma level of antimicrobial peptide LL37 is a major determinant factor of neonatal plasma LL37 level. Acta Paediatr 2010; 99(6):836–41.
  25. Gombart AF, O’Kelly J, Saito T, Koeffler HP. Regulation of the CAMP gene by 1, 25(OH)2D3 in various tissues. J Steroid Biochem Mol Biol 2007;103(3–5):552–7.
  26. Telcian AG, Stanciu LA. Vitamin D increases the antiviral activity of bronchial epithelial cells in vitro. Antiviral Res 2017;137:93-101.
  27. Jeng L, Yamshchikov AV, Judd SE, Blumberg HM, Martin SG, Ziegler TR, Tangpricha V. Alterations in vitamin D status and anti-microbial peptide levels in patients in the intensive care unit with sepsis. J Transl Med 2009;7:28.
  28. Albanna EA, Ali YF, Elkashnia R AM. Vitamin D and LL-37 in children with pneumonia. Egypt J Pediatr Allergy Immunol 2010;8(2):81–6.
  29. Georgieva V, Κamolvit W, Herthelius M, Luthje P, Brauner A, Chromek M. Association between vitamin D, antimicrobial peptides and urinary tract infection in infants and young children. Acta Paediatr 2019;108(3):551-6.
  30. Cakir E, Torun E, Gedik H, Umutoglu T, Actas EC, Topuz U, Deniz G. Cathelicidin and human b-defensin 2 in bronchoalveolar lavage fluid of children with pulmonary tuberculosis. Int J Tuberc Lung Dis 2014; 18(6):671-5.
  31. Beigelman A, Castro M, Schweiger TL, Wilson BS, Zheng J, Yin-DeClue H, Sajol G, Giri T, Sierra OL, Isaacson-Schmid M, et al. Vitamin D Levels Are Unrelated to the Severity of Respiratory Syncytial Virus Bronchiolitis Among Hospitalized Infants. J Pediatric Infect Dis Soc 2015;4(3):182-8.
  32. Moreno-Solís G, Fernández-Gutiérrez F, Torres-Borrego J, Torcello-Gáspar R, Gómez-Chaparro Moreno JL, Pérez-Navero JL. Low serum 25-hydroxyvitamin D levels and bronchiolitis severity in Spanish infants. Eur J Pediatr 2015;174(3):365-72.
  33. Vo P, Koppel C, Espinola J, Mansbach J, Celedon J, Hasegawa K, Bair-Merritt M, Camargo CA. Vitamin D status at the time of hospitalization for bronchiolitis and its association with disease severity. J Pediatr 2018;203:416-22.
  34. Wnorowska U, Fiedoruk K, Piktel E, Prasad SV, Sulik M, Janion M, , Daniluk T, Savage PB, Bucki R. Nanoantibiotics containing membrane-active human cathelicidin LL-37 or synthetic ceragenins attached to the surface of magnetic nanoparticles as novel and innovative therapeutic tools: current status and potential future applications, J Nanobiotechnology 2020;18(1):3.
  35. Wang G, Narayana JL, Mishra B, Zhang Y, Wang F, Wang C, Zarena D, Lushnikova T, Wang X. Design of Antimicrobial Peptides: Progress Made with Human Cathelicidin LL-37. Adv Exp Med Biol 2019;1117:215-40.
  36. Kozhikhova KV, Shilovskiy IP, Shatilov AA, Timofeeva AV, Turetskiy EA, Vishniakova LI, Nikolskij AA, Barvinskaya ED, Karthikeyan S, Smirnov VV et al. Linear and dendrimeric antiviral peptides: design, chemical synthesis and activity against human respiratory syncytial virus. J Mater Chem B 2020;8(13):2607-17.